tbuckley/cabot-search huggingface dataset:
A Randomized Trial to Reduce Disparities in Referral for Transplant Evaluation
Authors: Rachel E. Patzer, Sudeshna Paul, Laura Plantinga, Jennifer Gander, Leighann Sauls, Jenna Krisher, Laura L. Mulloy, Eric M. Gibney, Teri Browne, Carlos F. Zayas, William M. McClellan, Kimberly Jacob Arriola, Stephen O. Pastan
Journal: Journal of the American Society of Nephrology (2016)

Georgia has the lowest kidney transplant rates in the United States and substantial racial disparities in transplantation. We determined the effectiveness of a multicomponent intervention to increase referral of patients on dialysis for transplant evaluation in the Reducing Disparities in Access to kidNey Transplantation Community Study (RaDIANT), a randomized, dialysis facility–based, controlled trial involving &gt;9000 patients receiving dialysis from 134 dialysis facilities in Georgia. In December of 2013, we selected dialysis facilities with either low transplant referral or racial disparity in referral. The intervention consisted of transplant education and engagement activities targeting dialysis facility leadership, staff, and patients conducted from January to December of 2014. We examined the proportion of patients with prevalent ESRD in each facility referred for transplant within 1 year as the primary outcome, and disparity in the referral of black and white patients as a secondary outcome. Compared with control facilities, intervention facilities referred a higher proportion of patients for transplant at 12 months (adjusted mean difference [aMD], 7.3%; 95% confidence interval [95% CI], 5.5% to 9.2%; odds ratio, 1.75; 95% CI, 1.36 to 2.26). The difference between intervention and control facilities in the proportion of patients referred for transplant was higher among black patients (aMD, 6.4%; 95% CI, 4.3% to 8.6%) than white patients (aMD, 3.7%; 95% CI, 1.6% to 5.9%; P &lt;0.05). In conclusion, this intervention increased referral and improved equity in kidney transplant referral for patients on dialysis in Georgia; long-term follow-up is needed to determine whether these effects led to more transplants.
Adolescents and Young Adults With Hemophagocytic Lymphohistiocytosis Who Undergo Allogeneic Hematopoietic Cell Transplantation Are At Increased Risk Of Mortality Compared To Younger Patients
Authors: Shanmuganathan Chandrakasan, Rebecca Marsh, Michael Grimley, Jack Bleesing, Michael Jordan, Alexandra H. Filipovich
Journal: Blood (2013)
A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E,
Authors: Sarit Assouline, Biljana Kraljacic-Culjkovic, Eftihia Cocolakis, Abdellatif Amri, Julie Bergeron, Rahima Jamal, Wilson H. Miller, Katherine LB Borden
Journal: Blood (2011)
Prior Treatment with Chemotherapy Is Associated with Poor Outcomes of High Risk Skin Cancers in Patients with Chronic Lymphocytic Leukemia
Authors: Matthew S. Davids, Nicole F. Velez, Pritesh Karia, Ye Guo, Alexander R. Vartanov, Victor A. Neel, Jennifer R. Brown, Chrysalyne D. Schmults
Journal: Blood (2012)
Changes to the Definition of Posttraumatic Stress Disorder in the <i>DSM-5</i>—Reply
Authors: Matthew J. Friedman, Dean G. Kilpatrick, Paula P. Schnurr
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
MRI/optical dual-modality imaging of vulnerable atherosclerotic plaque with an osteopontin-targeted probe based on Fe 3 O 4 nanoparticles
Authors: Hongyu Qiao, Yabin Wang, Ruohan Zhang, Quansheng Gao, Xiao Liang, Lei Gao, Zhenhua Jiang, Ruirui Qiao, Dong Han, Yan Zhang, Ya Qiu, Jie Tian, Mingyuan Gao, Feng Cao
Journal: Biomaterials (2016)
TCT-546 6-Month Angiographic Results of the Novel MIRAGE Microfiber Sirolimus-Eluting Bioresorbable Vascular Scaffold - A Quantitative Coronary Angiography Analysis from the Prospective, Randomized MIRAGE Clinical Trial
Authors: Ricardo A. Costa, Houng-Bang Liew, Alexandre Abizaid, José de Ribamar Costa, Daniel Chamié, Andrea Abizaid, Juliana P. Castro, Patrick W. Serruys, Teguh Santoso
Journal: Journal of the American College of Cardiology (2015)
B Cells with BCL2/IGH Translocation Compose a Distinctive Cell Population That May Serve as a Reservoir of Lymphoma of Germinal Center B-Cell Type.
Authors: Tomomi Sakai, Momoko Nishikori, Masaharu Tashima, Ryo Yamamoto, Toshio Kitawaki, Akifumi Takaori-Kondo, Shinobu Tsuzuki, Takashi Uchiyama
Journal: Blood (2008)
Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation
Authors: Zhaogang Yang, Jing Xie, Jing Zhu, Chen Kang, Chiling Chiang, Xinmei Wang, Xiaobing Wang, Tairong Kuang, Feng Chen, Zhou Chen, Aili Zhang, Bo Yu, Robert J. Lee, Lesheng Teng, L. James Lee
Journal: Journal of Controlled Release (2016)
Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies
Authors: Aristoteles Giagounidis, Alan F. List, Eva Hellström-Lindberg, Ghulam J. Mufti, Brigitte Schlegelberger, John Morrill, Chengqing Wu, Barry S. Skikne, Pierre Fenaux, Gudrun Göhring
Journal: Blood (2015)
Risk adapted surveillance for stage I non–seminomatous testicular tumors (NSGCT). Results of a prospective multicenter study
Authors: P. Maroto-Rey, X. García Del Muro, L. Paz-Ares, J. Aparicio, J. Sastre, J. Dorca, J. Terrassa, J. A. Arranz, J. Barnadas, J. R. Germa
Journal: Journal of Clinical Oncology (2004)

4524 Background: Management of stage I NSGCT is controversial. Our challenge in the Spanish Germ Cell Group composed of 60 hospitals was to reduce morbidity through a risk adapted surveillance protocol useful regardless of size of Hospital or geographical differences. Methods:From I/94 to II/2003, 593 patients with stage I NSGCT entered a risk-adapted surveillance protocol. 360/593, 60.7% were in close follow-up (chest X ray and serum tumor markers every 2 m first year, every 3 m second year, every 4 m the third; abdominal Ct scan every other outpatient visit). 233/593, 39.3% received adjuvant BEP because vascular invasion in 150 patients, invasion of structures (considered as risk factor the first 3 years of our protocol) in 75 and other reasons in 8 (i.e. patient's choice). Chemotherapy consisted until 1999 of 3 cycles of Spanish BEP (Bleomicin 30 U/wk, Etoposide 100 mg/m2x4, Cisplatinum 25 mg/m2x4), later of 2 cycles and 21 patients received only one cycle. Results: Median follow-up: 40 m. Chemotherapy: No cancer specific mortality. Only 3 patients relapsed, at 12, 12.7 and 14.5 m and presently free of disease. Surveillance: 18 patients lost on follow-up. Six patients died of cancer. 73 (20%) patients relapsed, most of them within the first year. Seven years disease free survival of 76%. Relapses under surveillance: Only factor associated to relapse was Embrionary Carcinoma as the main component of histology.Eight patients presented a second testicular tumor on follow-up. Conclusions: Risk adapted surveillance provided a low rate of recurrences. In our area, reduction of relapses may reduce morbidity (lower number of surgery procedures or cycles per patient). Spanish BEP reduced number of recurrences almost to zero. Patients who received chemotherapy may simplify their follow-up. Further information about toxicity and pattern of relapse will be provided at the meeting. No significant financial relationships to disclose.
TCT-272 Everolimus-eluting stent versus bare-metal stent in diabetic patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial
Authors: Pilar Jimenez-Quevedo, Salvatore Brugaletta, Angel Cequier, Andres Iñiguez Romo, Antonio Serra, Vicente Mainar, Marco Valgimigli, Maurizio Tespili, Nieves Gonzalo, Patrick W. Serruys, Manel Sabate
Journal: Journal of the American College of Cardiology (2015)
Acute Occupational Pesticide-Related Illness and Injury —United States, 2007–2011
Authors: Geoffrey M. Calvert, John Beckman, Joanne Bonnar Prado, Heidi Bojes, Abby Schwartz, Prakash Mulay, Kathy Leinenkugel, Sheila Higgins, Michelle Lackovic, Justin Waltz, Derry Stover, Stephanie Moraga-McHaley
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

CDC's National Institute for Occupational Safety and Health (NIOSH) collects data on acute pesticide-related illness and injury reported by 12 states (California, Florida, Iowa, Louisiana, Michigan, Nebraska, North Carolina, New Mexico, New York, Oregon, Texas, and Washington). This report summarizes the data on illnesses and injuries arising from occupational exposure to conventional pesticides from 2007 through 2011. This report is a part of the Summary of Notifiable Noninfectious Conditions and Disease Outbreaks - United States, which encompasses various surveillance years but is being published in 2016 (1). The Summary of Notifiable Noninfectious Conditions and Disease Outbreaks appears in the same volume of MMWR as the annual Summary of Notifiable Infectious Diseases (2). In a separate report, data on illnesses and injuries from nonoccupational exposure to pesticides during 2007-2011 are summarized (3).
Quantitative RT-PCR Assessment of Cannabinoid Receptor CB2 and Fatty Acid Amine Hydrolase in Neoplastic Cells of Patients with B-Cell Chronic Lymphocytic Leukaemia.
Authors: Jaroslaw A. Piszcz, Janusz S. Kloczko, Slawomir Ziarko, Piotr Radziwon, Katarzyna Z. Mazgajska-Barczyk
Journal: Blood (2005)
DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1
Authors: Jie Xu, Wu Zhang, Xiao-Jing Yan, Xue-Qiu Lin, Wei Li, Jian-Qing Mi, Jun-Min Li, Jiang Zhu, Zhu Chen, Sai-Juan Chen
Journal: Journal of Hematology & Oncology (2016)

DNMT3A mutations are frequently discovered in acute myeloid leukemia (AML), associated with poor outcome. Recently, a relapse case report of AML extramedullary disease has showed that AML cells harboring DNMT3A variation were detected in the cerebral spinal fluid. However, whether a causal relationship exists between DNMT3A mutation (D3Amut) and extramedullary infiltration (EMI) is unclear.We took advantage of DNMT3A (R882C) mutation-carrying AML cell strain, that is, OCI-AML3, assessing its migration ability in vitro and in vivo. By RNA interfering technology and a xenograft mouse model, we evaluated the effect of DNMT3A mutation on cell mobility and explored the possible mechanism.OCI-AML3 displayed extraordinary migration ability in vitro and infiltrated into meninges of NOD/SCID mice after intravenous transfusion. We found that this leukemic migration or infiltration capacity was significantly compromised by the knockdown of DNMT3A mutant. Notably, TWIST1, a critical inducer of epithelial-mesenchymal transition, which underlies the metastasis of carcinomas, was highly expressed in association with R882 mutations. Abrogation of TWIST1 in DNMT3A mutated cells considerably weakened their mobility or infiltration.Our results demonstrate that D3Amut in OCI-AML3 strain enhances leukemic aggressiveness by promoting EMI process, which is partially through upregulating TWIST1.
Oxaliplatin (Ox) and raltitrexed (Ral) as first line treatment for locally advanced and metastatic gastric adenocarcinoma: Results of an ONCOPAZ phase II trial (OPHA 0141)
Authors: J. I. Chacón, J. Feliú, J. A. G. Saenz, E. Fonseca, L. M. Anton, M. Bolaños, J. R. Mel, P. Escudero, J. M. Vicent, M. G. Baron
Journal: Journal of Clinical Oncology (2004)

4213 Background: No data exist about efficacy of the combination of Ox and Ral for treatment of advanced gastric adenocarcinoma, a doublet that might be active in this disease. Methods: A multicenter phase II trial was launched in Aug 2002. Primary objectives were: response rate and toxicity. Eligible pts: locally advanced or metastasic gastric adenocarcinoma; at least 1 measurable lesion, ECOG 0–2, CrCl> 65 ml/min. Therapy: Ral 3 mg/m2 IV day 1; Ox 130 mg/m2 IV day 1; cycles every 3 weeks. Treatment until progression or unacceptable toxicity. Results: : 47 patients were enrolled. Data provided from 42 pts. 35 M (83.3%), 7 F (18.7%). Median age: 63 (range: 29–77). Stages: IIIA: 3 (7.5%); IIIB: 3 (7.5%); IV: 34 (85%). Total number of Cycles: 194. Median number of cycles: 4 (range: 1–13). Response rate (by intention to treat): 36 patients valuables for response. CR: 0; PR: 15 (35,7%); EE: 8 (19%); P: 13 (30.9%); non evaluable: 6 (14%). Toxicity: Grade 3–4 toxicities were (by number of cycles): Neutropenia: 3 (1.8%); Haemoglobin: 2 (1.2%); platelets: 1 (0.6%); AST/ALT increase: 12 (8.1%); nausea: 7 (4.2%); vomiting: 5 (3%); diarrhoea: 4 (2.4%); asthenia: 10 (6.3%); mucositis: 0%; neuropathy-motor: 1 (0.6%); neuropathy-neurosory: 3 (2.6%). Neurosensory toxicity grades 1–2 was present in 37% of cycles. 1 febrile neutropenia episode was produced in one patient, with septic shock and death (considered as toxic death). Survival: Median OS is of 5,9 months (IC 95%: 4.6–6.3 months). Conclusions: Oxaliplatin-raltitrexed is not enough active in gastric cancer to warrant further studies. General toxicity of the combination is very low, although unexpected severe, potentially letal toxicity, may appear in some patients. No significant financial relationships to disclose.
Phase II Study of Chemotherapy (Cx) and Stem Cell Transplantation (SCT) for Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LBL): Long-Term Follow-up Results of Japan Clinical Oncology Group (JCOG) Study 9402.
Authors: Teruhisa Azuma, Kensei Tobinai, Kunihiko Takeyama, Taro Shibata, Haruhiko Fukuda, Fumio Kawano, Keiko Aikawa, Masaharu Kasai, Takaaki Chou, Masayuki Sano, Kuniaki Itoh, Toshiaki Sai, Hisashi Yamada, Kiyoshi Mukai, Tomomitsu Hotta, Masanori Shimoyama
Journal: Blood (2009)
TCT-318 Near-infrared Spectroscopy-derived Maximum Lipid Core Burden Index in the Culprit Plaque of Patients with ST-elevation Myocardial Infarction Increases with Age
Authors: Sofia Karlsson, Matthias Gotberg, Pontus Andell, Goran K. Olivecrona, David Erlinge
Journal: Journal of the American College of Cardiology (2015)
Effect of tumor-associated antigens on specific T-cell responses in patients with metastatic lung cancer and potential use as immunogenic targets for a (polyvalent) vaccination strategy.
Authors: A. M. Babiak, M. Steinhauser, H. Dohner, J. Greiner
Journal: Journal of Clinical Oncology (2010)

e13064 Background: In spite of many attempts to improve overall survival and to prolong the relapse-free survival in advanced and metastatic lung cancer, therapeutic approaches including chemotherapy and radiation have reached a plateau of efficacy. Therefore, new strategies of tumor therapy have been investigated like immunotherapeutic approaches. Tumor cells can be efficiently killed by specific T-cells of the immune system. Methods: We investigated the frequency of specific T-cell responses of CD8-positive T cells against several known but also newly characterized HLA-A2-restricted epitopes derived from the tumor-associated antigens MAGE-A3, RHAMM, hTERT, Survivin, WT-1, PRAME, HER2/neu, and G250 in patients with metastatic lung cancer. For new epitopes HLA-A2-binding motifs were predicted using computer analysis based on known binding affinities. More than 10 peptides with most favorable characteristics were evaluated in ELISPOT assays for interferon gamma and granzyme B secretion by CD8 positive T cells in patients with metastatic lung cancer. Results: Specific T-cell responses could be detected against at least one peptide in all patients with non-small cell lung cancer before treatment with chemotherapy. Most frequent responses could be detected (50% or more of patients) against a peptide derived from hTERT and PRAME. Lower frequency of specific T-cell responses was found for Survivin- (40%), G250- (33%), and MageA3-derived peptides (20%), no responses against RHAMM-, HER2neu-, and WT1-derived peptides. Conclusions: Taken together, specific T- cell responses against several TAAs could be detected for the antigens hTERT and PRAME in 50% or more of patients with lung cancer, but also in a lower frequency against MAGEA3, G250 and Survivin peptides. Therefore, immunotherapeutic approaches targeting these antigen structures is a new therapeutic option for these patients in advanced lung cancer. No significant financial relationships to disclose.
Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse
Authors: Costa Bachas, Gerrit J. Schuurhuis, Lê D Huynh, Bianca F. Goemans, D. Reinhardt, Gertjan Kaspers, Jacqueline Cloos
Journal: Blood (2008)
GW27-e0524 Predictors of Successful Recanalization in Patients with Native Coronary Chronic Total Occlusion: The B-CTO (Busan Single-center CTO Registry) Score
Authors: Cai De Jin, Moo Hyun Kim, Kwang Min Lee, Tae Hyung Kim, Young-Rak Cho, Victor Serebruany
Journal: Journal of the American College of Cardiology (2016)
Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies
Authors: Robert J Soiffer, Jennifer LeRademacher, Vincent T Ho, Fangyu Kan, Andrew Artz, Richard Champlin, Steven Devine, Hillard M. Lazarus, David I Marks, David Porter, Edmund K. Waller, Mary M. Horowitz, Mary Eapen
Journal: Blood (2010)
TCT-106 Cardiovascular Magnetic Resonance for the Evaluation of Aortic Regurgitation Following Transcatheter Aortic Valve Replacement: Insights on Clinical Outcomes
Authors: Henrique B. Ribeiro, Stefan Orwat, Salim S. Hayek, Eric Larose, Vasilis Babaliaros, Abdellaziz Dahou, Sergio Pasian, Philippe Pibarot, Emilie Pelletier Beaumont, Francisco Campelo-Parada, Stamatios Lerakis, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2015)
Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid tumors.
Authors: J. B. Vermorken, J. H. Machiels, S. Rottey, H. C. Thurm, K. Pelling, A. Lahogue
Journal: Journal of Clinical Oncology (2010)

e13521 Background: BIBW 2992 is a novel, potent, orally bioavailable irreversible inhibitor of EGFR/HER1 and HER2 receptor tyrosine kinases. In addition, BIBW 2992 displays potent activity in cases of EGFRvIII mutation. Methods: The primary objective of this phase I trial was to determine the MTD of BIBW 2992 given orally as a continuous once-daily dose when combined with PT (regimen A) or PF (regimen B) in patients (ptns) with advanced solid tumors. Doses given in A: BIBW 2992 20 mg → 50 mg combined with 21-day cycles of P 50 mg/m2 → 75 mg/m2 and T 175 mg/m2; and in B: BIBW 2992 20 mg → 50 mg combined with 21-day cycles of P 75 mg/m2 → 100 mg/m2 and 5-FU 750 mg/m2 → 1,000 mg/m2. Results: 47 ptns were treated (median age: 60 years, median ECOG performance status of 1, median lines of prior chemotherapy: 2) with various solid tumors (11 ptns with tumors of the gastrointestinal tract [GI] tumors, 10 ptns with head and neck tumors [H&N], 7 ptns with gynaecological tumors [GYN], 4 ptns with tumors of the genitourinary tract [GU], 3 melanoma ptns, and 12 ptns with other tumors). The MTD in A was BI 40 mg - P 75 mg/m2 - T 175 mg/m2. DL AEs in cycle 1 included asthenia grade (G) 3, AST/ALT increase G 3, glossitis G 3 and fatal febrile neutropenia (one ptn each). MTD in B was BI 30 mg - P 100 mg/m2 and 5-FU 750 mg/m2, with uncontrollable G3 diarrhea, G3 stomatits, G2 serum creatinine increase, and G3 mucositis in cycle 1, each time in one ptn. One ptn developed both G3 thrombopenia and G3 fatigue. Altogether, there were 39/45 (87%) ptns with at least one AE of G 3/4 during all cycles. In A, 6 ptns showed a PR (3 ptns with GYN, 2 ptns with GI, 1 ptn with H&N) and 11 ptns revealed SD for 3 to 17 cycles. In B, one ptn with H&N responded with a CR for 28 weeks, 3 ptns responded with PR (2 ptns with H&N, one ptn with GYN) ptns responded while 8 ptns showed SD (for 2 to 7 cycles). Conclusions: The MTD of BIBW 2992 for regimen B is 30 mg and is under discussion for regimen A. Taking both regimens together, responses have been observed in 10/47 (21%) ptns including one ptn with a complete response. 19/47 (40%) ptns showed disease stabilization. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Boehringer Ingelheim Boehringer Ingelheim Boehringer Ingelheim
Impact of Myocardial Infarction On Survival in Acute Myeloid Leukemia
Authors: Joshua Lukenbill, Paul Elson, Sanjay Mohan, Ramon V. Tiu, Yogen Saunthararajah, Leslie Farhat, Cassandra Kendeigh, Anjali Advani, Edward A. Copelan, Matt Kalaycio, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2012)
TCT-651 Acceleration time and Low Flow, Low Gradient, Severe Aortic Stenosis: Correlation and Prediction of Valve Area
Authors: Deepakraj Gajanana, Vikas Bhalla, Jose N. Codolosa, Gregg Pressman, Sean F. Janzer, Dennis L. Morris, Vincent M. Figueredo
Journal: Journal of the American College of Cardiology (2015)